China holds a \u00a0dominant position\u00a0 in the global photovoltaic cell market, accounting for an astonishing \u00a080%\u00a0 of the total market share. Recent reports indicate that its manufacturing capacity is a staggering \u00a017 times greater than the rest of the world combined\u00a0. This unparalleled production capacity has prompted the Chinese government to bolster the manufacturing of \u00a0more than 1,000 GW in N-type cell capacity\u00a0 as international commitments to net emissions standards evolve. As more countries fulfill these commitments, China’s supremacy in the solar energy sector remains largely unchallenged, although \u00a0India is emerging as a potential disruptor\u00a0 in the long run.<\/p>\n
<\/p>\n
Beyond solar cells, China is also the world’s leading producer of \u00a0lithium batteries\u00a0. In the realm of electric vehicles (EVs), it manufactures \u00a057%\u00a0 of the batteries utilized worldwide. Leading the charge are companies like \u00a0CATL and BYD\u00a0, which boast a combined market share of \u00a034%\u00a0 and \u00a016%\u00a0, respectively. This overwhelming dominance in two critical sectors is attributed to a strategic focus on \u00a0investments in research and development (R&D)\u00a0 and large-scale production, enhancing competitiveness. Now, Chinese biopharmaceutical firms aim to replicate this success formula in the medical sector.<\/p>\n
<\/p>\n
According to \u00a0Da Liu\u00a0, Managing Director of the CR-CP Life Science Fund, “We can reduce the costs of medical care and benefit more people through technological innovation and efficiency improvement.” This powerful statement underscores the potential for \u00a0biotechnology advancements\u00a0 to influence healthcare costs dramatically. The CR-CP Fund is a coalition of the Chinese state and Thailand’s Pokphand Group, formed to invest in promising biotechnology enterprises.<\/p>\n
<\/p>\n
“We can reduce medical care costs and benefit more people through technological innovation and efficiency improvement.”<\/p>\n<\/p><\/div>\n<\/div>\n
Chinese pharmaceutical and biotechnology sectors are experiencing a \u00a0“Deepseek” moment.\u00a0 This term signifies a growing demand from multinational corporations for drugs developed in China rather than starting from scratch. The implications are huge\u2014these global players are eager to obtain licenses to produce or distribute Chinese-developed medicines.<\/p>\n
<\/p>\n
In a recent report by the American investment bank \u00a0Jefferies\u00a0, it was highlighted that Chinese companies are exceptionally competitive due to their \u00a0efficiency in costs, short turnaround times\u00a0, and the \u00a0quality\u00a0 of their products. Notably, of the top ten agreements in the pharmaceutical industry during the first half of 2025, \u00a0seven involved Chinese licenses\u00a0, according to \u00a0Pharmcube\u00a0, a consultancy specializing in pharmaceuticals.<\/p>\n
<\/p>\n
The success of China’s pharmaceutical sector stems from a strategy mirroring the winning tactics in its solar and battery industries. However, challenges loom large. Geopolitical tensions, particularly between the U.S. and China, complicate the international growth prospects for Chinese biotechnology firms. \u00a0Liu states\u00a0 that to emerge as significant global players in the pharmaceutical field, these companies need to attain a dominant position in at least one or two biotech domains.<\/p>\n
<\/p>\n
Image | Edward Jenner<\/a><\/p>\n